Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenat...

Full description

Saved in:
Bibliographic Details
Main Authors: Can G. Leineweber (Author), Miriam Rabehl (Author), Anne Pietzner (Author), Nadine Rohwer (Author), Michael Rothe (Author), Maciej Pech (Author), Bruno Sangro (Author), Rohini Sharma (Author), Chris Verslype (Author), Bristi Basu (Author), Christian Sengel (Author), Jens Ricke (Author), Nils Helge Schebb (Author), Karsten-H. Weylandt (Author), Julia Benckert (Author)
Format: Book
Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available